BioRestorative Therapies, Inc. (NASDAQ:BRTX) has completed a public offering of approximately 14.3 million shares and accompanying warrants at $0.35 per share, generating roughly $5.0 million in gross proceeds. The offering represents a capital raise intended to support the company's expanding portfolio of regenerative medicine and biocosmetic initiatives.
The company intends to allocate the proceeds across multiple developmental priorities, including advancement of clinical trials for BRTX-100, its investigational stem cell therapy targeting disc and spine degenerative disease. Additional funding will support pre-clinical research efforts related to the ThermoStem Program, which focuses on therapeutic applications for metabolic disorders, as well as continued development of the company's commercial biocosmeceuticals platform.
The capital infusion provides BioRestorative with resources to accelerate its clinical and research timelines while maintaining operational flexibility. The funds will also be available for general corporate purposes as the company continues to execute its strategic development roadmap.